<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        224-368-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BRIMOCOM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE,BRIMONIDINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01ED51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Brimocom&trade; is an eye drop that is used to control<br />glaucoma. It contains two different medicines<br />(brimonidine and timolol) that both reduce high<br />pressure in the eye. Brimonidine belongs to a group<br />of medicines called alpha-2 adrenergic receptor<br />agonists. Timolol belongs to a group of medicines<br />called beta-blockers. Brimocom&trade; is prescribed to<br />reduce high pressure in the eye when beta-blocker<br />eye drops used alone are not enough.<br />Your eye contains a clear, watery liquid that feeds<br />the inside of the eye. Liquid is constantly being<br />drained out of the eye and new liquid is made to<br />replace this. If the liquid cannot drain out quickly<br />enough, the pressure inside the eye builds up and<br />could eventually damage your sight. Brimocom&trade;<br />works by reducing the production of liquid and<br />increasing the amount of liquid that is drained. This<br />reduces the pressure inside the eye whilst still<br />continuing to feed the eye.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Brimocom&trade; eye drops solution<br />&bull; if you are allergic (hypersensitive) to brimonidine<br />tartrate, timolol, beta-blockers or any of the other<br />ingredients of Brimocom&trade;. Symptoms of an<br />allergic reaction may include swelling of the face,<br />lips and throat, wheeziness, feeling faint, shortness<br />of breath, itching or redness around the eye.<br />&bull; if you have now or have had in the past respiratory<br />problems such as asthma, severe chronic<br />obstructive bronchitis(severe lung disease which<br />may cause wheeziness, difficulty in breathing and/or<br />long-standing cough).<br />&bull; if you have heart problems such as low heart rate,<br />heart failure, heart beat disorders<br />(unless controlled by a pacemaker).<br />&bull; if you are taking monoamine oxidase (MAO)<br />inhibitors or certain other antidepressant drugs.<br />Brimocom&trade; should not be used in infants less than<br />2 years old and should not usually be used in<br />children aged 2 to 17 years .<br />If you think any of these points apply to you, do not<br />use Brimocom&trade; until you have talked again to your<br />doctor.<br />Take special care with Brimocom&trade;<br />Before you take this medicine, tell your doctor<br />&bull; if you have now or have had in the past<br />- coronary heart disease (symptoms can include<br />chest pain or tightness, breathlessness or choking),<br />heart failure, low blood pressure<br />- disturbances of heart rate such as slow heart beat<br />- breathing problems, asthma or chronic obstructive<br />pulmonary disease<br />- poor blood circulation disease (such as Raynaud&rsquo;s<br />disease or Raynaud&rsquo;s syndrome)<br />- diabetes as timolol may mask signs and symptoms<br />of low blood sugar levels<br />- over activity of the thyroid gland as timolol may<br />mask signs and symptoms<br />- kidney or liver problems<br />- tumour of the adrenal gland<br />- eye surgery to lower the pressure in your eye<br />&bull; if you suffer or have suffered from any allergy<br />(e.g. hayfever, eczema) or a severe allergic reaction<br />be aware that the usual dose of adrenaline used to<br />control a severe reaction may need to be increased.<br />&bull; Tell the doctor before you have an operation that<br />you are using Brimocom&trade;, as the timolol may<br />change effects of some medicines during<br />anaesthesia.<br />Using other medicines<br />Brimocom&trade; can affect or be affected by other<br />medicines you are using, including other eye<br />drops for the treatment of glaucoma. Please tell<br />your doctor or pharmacist if you are taking or have<br />recently taken any other medicines, including<br />medicines for any condition, even if unrelated to<br />your eye condition, including medicines obtained<br />without a prescription. There are a number of<br />medicines which may interfere with Brimocom&trade;,<br />so it is particularly important to tell your doctor if<br />you are taking:<br />&bull; pain killers<br />&bull; medicines to help you sleep or for anxiety<br />&bull; medicines to treat high blood pressure<br />(hypertension)<br />&bull; medicines for heart conditions (for example an<br />abnormal heartbeat) such as beta blockers,digoxin or<br />quinidine (used to treat heart conditions and some<br />types of malaria)<br />&bull; medicines to treat diabetes or high blood sugar<br />&bull; medicines for depression such as fluxetine and<br />paroxetine<br />&bull; another eye drop used to lower high pressure in the<br />eye (glaucoma)<br />&bull; medicines to treat severe allergic reactions<br />&bull; medicines that affect some of the hormones in your<br />body, like adrenaline and dopamine<br />&bull; medicines that affect the muscles in your blood<br />vessels<br />&bull; medicines to treat heartburn or stomach ulcers<br />If the dose of any of your current medicines is<br />changed or if you are regularly consuming alcohol<br />you should tell your doctor.<br />If you are due to have an anaesthetic, you should tell<br />the doctor or dentist that you are taking<br />Brimocom&trade;.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before<br />taking any medicine. Tell your doctor if you are<br />pregnant or planning to become pregnant.<br />Do not use Brimocom&trade; if you are pregnant unless<br />your doctor considers it necessary.<br />Do not use Brimocom&trade; if you are breast-feeding.<br />Timolol may get into your milk. Ask you doctor for<br />advice before taking any medicine during<br />breast-feeding.<br />Driving and Using Machines<br />Brimocom&trade; may cause drowsiness, tiredness or<br />blurred vision in some patients. Do not drive or use<br />any tools or machines until the symptoms have<br />cleared. If you experience any problems, talk to<br />your doctor.<br />Important information about some of the<br />ingredients of Brimocom&trade;<br />Contact Lenses<br />&bull; Do not use Brimocom&trade; while your contact lenses<br />are in your eyes. Wait at least 15 minutes after using<br />Brimocom&trade; before putting your lenses back in.<br />&bull; A preservative in Brimocom&trade; (benzalkonium<br />chloride) may cause eye irritation and is also known<br />to discolour soft contact lenses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Brimocom&trade; exactly as your doctor has<br />told you. You should check with your doctor or<br />pharmacist if you are not sure. Brimocom&trade; must<br />not be used in infants below 2 years of age.<br />Brimocom&trade; should not usually be used in children<br />and adolescents (from 2 to 17 years).<br />The usual dose is one drop of Brimocom&trade;, twice a<br />day about 12 hours apart. Do not change the dose or<br />stop taking it without speaking to your doctor.<br />If you have other eye drops as well as Brimocom&trade;,<br />leave at least 5 minutes between using<br />Brimocom&trade; and the other eye drops.<br />Instructions for use<br />Wash your hands before opening the bottle. Tilt<br />your head back and look at the ceiling.<br />1. Gently pull down the lower eyelid until there is a<br />small pocket.<br />2. Turn the bottle upside down and squeeze it to<br />release one drop into each eye that needs treatment.<br />3. Let go of the lower lid, and close your eye.<br />4. Keep the eye closed and press your finger against<br />the corner of your eye (the side where your eye<br />meets your nose) for two minute. This helps stop<br />Brimocom&trade; getting into the rest of the body.<br />If a drop misses your eye, try again.<br />To avoid contamination, do not let the tip of the<br />bottle touch your eye or anything else. Put the<br />screw-cap back on to close the bottle, straight after<br />you have used it.<br />If you use more Brimocom&trade; than you should<br />Adults<br />If you use more Brimocom&trade; than you should, it is<br />unlikely to cause you any harm. Put your next drop<br />in at the usual time. If you are worried, talk to your<br />doctor or pharmacist.<br />Babies and Children<br />Several cases of overdose have been reported in<br />babies and children receiving brimonidine (one of<br />the ingredients of Brimocom&trade;) as part of medical<br />treatment for glaucoma. Signs include sleepiness,<br />floppiness, low body temperature, paleness and<br />breathing difficulties. Should this happen, contact<br />your doctor immediately.<br />Adults and Children<br />If Brimocom&trade; has been accidentally swallowed<br />then you should contact your doctor immediately.<br />If you forget to use Brimocom&trade;<br />If you forget to use Brimocom&trade;, use a single drop<br />in each eye that needs treatment as soon as you<br />remember, and then go back to your regular routine.<br />Do not take a double dose to make up for a forgotten<br />dose.<br />If you stop using Brimocom&trade;<br />Brimocom&trade; should be used every day to work<br />properly.<br />If you have any further questions on the use of this<br />product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Brimocom&trade; can cause side<br />effects, although not everybody gets them. If you<br />experience any of the following side effects, please<br />contact your doctor immediately:<br />&bull; Heart failure (eg. chest pain) or irregular heart<br />rate<br />&bull; Increased or decreased heart rate or low blood<br />pressure<br />The chance of having a side effect is described by<br />the following categories:<br />Not known:<br />Frequency cannot be estimated from the available<br />data<br />Very common:<br />Occurs in more than 1 out of 10 patients<br />Common:<br />Occurs in fewer than 1 out of 10 patients<br />Uncommon:<br />Occurs in fewer than 1 out of 100 patients<br />The following side effects may be seen with<br />Brimocom&trade;.<br />Affecting the eye<br />Very common: Eye redness or burning.<br />Common:<br />&bull; Stinging or pain in the eye<br />&bull; Allergic reaction in the eye or on the skin around<br />the eye<br />&bull; Small breaks in the surface of the eye (with or<br />without inflammation)<br />&bull; Swelling, redness or inflammation of the eyelid<br />&bull; Irritation, or a feeling of something in the eye<br />&bull; Itching of the eye and eyelid<br />&bull; Follicles or white spots on the see through layer<br />which covers the surface of the eye<br />&bull; Vision disturbance<br />&bull; Tearing<br />&bull; Eye dryness<br />&bull; Sticky eyes<br />Uncommon:<br />&bull; Difficulty in seeing clearly<br />&bull; Swelling or inflammation of the see-through layer<br />which covers the surface of the eye<br />&bull; Tired eyes<br />&bull; Sensitivity to light<br />&bull; Eyelid pain<br />&bull; Whitening of the see-through layer which covers<br />the surface of the eyes<br />&bull; Swelling or areas of inflammation under the<br />surface of the eye<br />&bull; Floaters in front of the eyes<br />Not known:<br />&bull; Blurred vision<br />Affecting the body:<br />Common:<br />&bull; High blood pressure<br />&bull; Depression<br />&bull; Sleepiness<br />&bull; Headache<br />&bull; Dry mouth<br />&bull; General weakness<br />Uncommon:<br />&bull; Heart failure<br />&bull; Irregular heart rate<br />&bull; Light-headedness<br />&bull; Fainting<br />&bull; Dry nose<br />&bull; Taste disturbance<br />&bull; Nausea<br />&bull; Diarrhoea<br />Not known:<br />&bull; Increased or decreased heart rate<br />&bull; Low blood pressure<br />&bull; Face redness<br />Some of these effects may be due to an allergy to<br />any of the ingredients. Additional side effects have<br />been seen with brimonidine or timolol and<br />therefore may potentially occur with Brimocom&trade;.<br />The following additional side effects have been<br />seen with brimonidine:<br />- inflammation within eye, small pupils, difficulty<br />sleeping, cold-like symptoms, shortness of breath,<br />symptoms involving the stomach and digestion,<br />general allergic reactions, skin reactions including<br />redness, face swelling itching rash and widening of<br />blood vessels.<br />Like other medicines applied into eyes,<br />Brimocom&trade; (brimonidine/timolol) is absorbed<br />into the blood. Absorption of timolol, a beta<br />blocker component of Brimocom&trade;, may cause<br />similar side effects as seen with intravenous&rdquo; and<br />/or &ldquo;oral&rdquo; beta-blocking agents. Incidence of side<br />effects after topical ophthalmic administration is<br />lower than when medicines are for example, taken<br />by mouth or injected. Listed side effects include<br />reactions seen within the class of beta-blockers<br />when used for treating eye conditions:<br />- Generalised allergic reactions, including swelling<br />beneath the skin (that can occur in areas such as<br />the face and limbs, and can obstruct the airway<br />which may cause difficulty swallowing or<br />breathing), hives (or itchy rash), localised and<br />generalised rash, itchiness, severe sudden life<br />threatening allergic reaction<br />- Low-blood glucose levels<br />- Difficulty in sleeping (insomnia), nightmares,<br />memory loss<br />- Stroke, reduced blood supply to the brain,<br />increased signs and symptoms of myasthenia<br />gravis (muscle disorder), unusual sensations (like<br />pins and needles).<br />- Inflammation in the cornea, detachment of the<br />layer below the retina that contains blood vessels<br />following filtration surgery which may cause visual<br />disturbances, decreased corneal sensitivity, corneal<br />erosion (damage to the front layer of the eyeball),<br />drooping of the upper eyelid (making the eye half<br />closed), double vision<br />- Chest pain, oedema (fluid build up), changes in<br />the rhythm or speed of the heartbeat, a type of<br />heart rhythm disorder, heart attack, heart failure<br />- Raynaud&rsquo;s phenomenon, cold hands and feet<br />- Constriction of the airways in the lung<br />(predominantly in patients with pre- existing<br />disease) difficulty breathing, cough<br />- Indigestion , abdominal pain, vomiting<br />- Hair loss, skin rash with white silvery coloured<br />appearance (psoriasiform rash) or worsening of<br />psoriasis, skin rash<br />- Muscle pain not caused by exercise<br />- Sexual dysfunction, decreased libido<br />- Muscle weakness/tiredness<br />If any of the side effects gets serious, or if you<br />notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Keep the bottle in the outer carton to protect it<br />from light.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Do not use Brimocom&trade; eye drops after the<br />expiry date which is stated on the label of the<br />bottle and the carton after EXP.<br />&bull; Brimocom&trade; eye drops are sterile when first<br />opened, it is important to keep the drops as clean as<br />possible during use.<br />&bull; Discard after 30 days of opening.<br />&bull; Medicines should not be disposed of via waste<br />water or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required.<br />This will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substances are brimonidine tartrate<br />and timolol.<br />&bull; Each ml contains 2 mg brimonidine tartrate and<br />timolol maleate equivalent to 5 mg of timolol.<br />&bull; The other ingredients are benzalkonium chloride<br />(a preservative), sodium dihydrogen phosphate<br />anhydrous, disodium hydrogen phosphate<br />anhydrous, sodium hydroxide (to adjust pH) and<br />water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Brimocom™ eye drops is a clear, greenish-yellow
solution free from visible particles,
• Brimocom™ eye drops solution, 5 ml filled in
LDPE opaque bottles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and<br />Manufacturer<br />Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region,<br />Saudi Arabia.<br />Tel: +966-12-6081111<br />Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12-09-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;<br />هو قطرة للعين يتم استخدامها للسيطرة على<br />الجلوكوما. و هو يحتوي على دوائين مختلفين (بريمونيدين و<br />تيمولول) و كلاهما يخفض الضغط المرتفع داخل العين. ينتمي<br />بريمونيدين إلى مجموعة من الأدوية تسمى منبهات مستقبلات<br />ألفا- ۲ الأدرينالية. وينتمي تيمولول إلى مجموعة من الأدوية<br />&trade; تسمى حاصرات بيتا. يوصف بريموكوم لخفض الضغط<br />المرتفع داخل العين عندما يكون إستخدام قطرات العين<br />المحتوية على حاصرات بيتا لوحدها غير كاف.<br />تحتوي العين على سائل مائي رائق يغذي العين من الداخل. هذا<br />السائل يتم صرفه من العين بصفة مستمرة ويتم استبداله بسائل<br />جديد. إذا لم تتم عملية صرف السائل بالسرعة الكافية، فإن<br />الضغط داخل العين يرتفع وقد يؤدي في النهاية إلى تلف<br />الإبصار. يعمل بريموكوم على تقليل إنتاج السائل وزيادة &nbsp;<br />صرفه. وهذا يقلل الضغط داخل العين مع الاستمرار في تغذية<br />العين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>بريموكوم<br />قطرة للعين محلول &trade; لا تستخدم بريموكوم<br />&bull; إذا كنت تعاني من التحسس (فرط الحساسية) من بريمونيدين<br />تارتارات، تيمولول، حاصرات بيتا أو أي من المكونات<br />ويمكن أن تشمل أعراض .&trade; الأخرى الموجودة في بريموكوم<br />الحساسية تورم في الوجه، الشفتين و الحلق، أزيز، شعور<br />بالإغماء، ضيق في التنفس، حكة أو احمرار حول العين.<br />&bull; إذا كان لديك الآن أو في الماضى مشاكل في الجهاز التنفسي<br />مثل الربو، التهاب القصبات الهوائية المزمن الحاد (مرض<br />رئوي حاد مما قد يتسبب في أزيز وصعوبة في التنفس و / أو<br />سعال طويل الأمد).<br />&bull; إذا كان لديك مشاكل في القلب مثل انخفاض معدل ضربات<br />القلب ، فشل القلب، واضطرابات في ضربات القلب (ما لم تكن<br />تحت السيطرة بجهاز تنظيم ضربات القلب).<br />أو (MAOIs) &bull; إذا كنت تأخذ مثبِّطُات أُحاديِّ أمين أوكسيديز<br />أنواع أخرى من الأدوية المضادة للإكتئاب.<br />في الرضع أقل من عمر &trade; لا ينبغي أن يستخدم بريموكوم<br />سنتين، و عادة لا ينبغي أن يستخدم في الأطفال الذين تتراوح<br />۱۷ سنة. - أعمارهم بين ۲<br />إذا كنت تعتقد أن أي من هذه النقاط تنطبق عليك، لا تستخدم<br />حتى تتحدث مرة أخرى مع طبيبك. &trade; بريموكوم<br />&trade; إتخذ إحتياطات خاصة عند إستخدام بريموكوم<br />قبل إستخدامك لهذا الدواء قم بإخبار طبيبك<br />&bull; إذا كان لديك الآن أو في الماضي<br />- مرض القلب التاجي (الأعراض يمكن أن تشمل ألم أو ضيق<br />في الصدر ، ضيق في التنفس أو اختناق)، فشل القلب، انخفاض<br />ضغط الدم<br />- اضطرابات في معدل ضربات القلب مثل بطء نظم القلب<br />- مشاكل التنفس، ربو أو مرض الانسداد الرئوي المزمن<br />- مرض ضعف الدورة الدموية (مثل مرض رينود أو متلازمة<br />رينود)<br />- مرض السكري حيث أن التيمولول قد يخفي علامات و<br />أعراض انخفاض مستويات السكر في الدم<br />- النشاط الزائد للغدة الدرقية حيث أن التيمولول قد يخفي<br />الأعراض والعلامات<br />- مشاكل في الكلى أو الكبد<br />- ورم بالغدة الجاركلوية<br />- جراحة في العين لخفض الضغط داخل العين<br />&bull; إذا كنت تعاني أو عانيت من أي حساسية (مثل حمى القش و<br />الإكزيما) أو أي تفاعل حساسية شديد، يجب أن تعرف أن<br />الجرعة المعتادة من الأدرينالين التي تستخدم للسيطرة على<br />التفاعل الشديد قد تحتاج أن تزداد.<br />&bull; أخبر الطبيب قبل الخضوع لعملية جراحية أنك تستخدم<br />حيث أن التيمولول قد يغير من تأثير بعض ،&trade; بريموكوم<br />الأدوية أثناء التخدير.<br />إستخدام أدوية أخرى<br />يمكن أن يؤثر على أو يتأثر بالأدوية الأخرى &trade; بريموكوم<br />التي تستخدمها، بما في ذلك قطرات العين الأخرى لعلاج<br />الجلوكوما. يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تستعمل أو<br />استعملت مؤخراً أي أدوية أخرى، بما في ذلك الأدوية لأي<br />حالة، حتى لو لم تكن لها علاقة بحالة عينك، بما في ذلك<br />الأدوية التي تم الحصول عليها بدون وصفة طبية. هناك عدد<br />لذلك من المهم ،&trade; من الأدوية التي قد تتداخل مع بريموكوم<br />بصفة خاصة أن تخبر طبيبك إذا كنت تستعمل:<br />&bull; مسكنات الألم<br />&bull; أدوية لمساعدتك على النوم أو علاج القلق<br />&bull; أدوية لعلاج ارتفاع ضغط الدم<br />&bull; أدوية لأمراض القلب (على سبيل المثال ضربات القلب غير<br />الطبيعية) مثل حاصرات بيتا، الديجوكسين أو الكينيدين (التي<br />تستخدم لعلاج أمراض القلب وبعض أنواع الملاريا)<br />&bull; أدوية لعلاج مرض السكري أو ارتفاع السكر في الدم<br />&bull; أدوية لعلاج الاكتئاب مثل فلوكستين و الباروكستين<br />&bull; قطرة عين أخرى تستخدم لخفض ارتفاع الضغط في العين<br />(الجلوكوما)<br />&bull; أدوية لعلاج الحساسية الشديدة<br />&bull; الأدوية التي تؤثر على بعض الهرمونات في الجسم، مثل<br />الأدرينالين و الدوبامين<br />&bull; الأدوية التي تؤثر على العضلات في الأوعية الدموية<br />&bull; الأدوية لعلاج حرقة المعدة أو القرحة<br />إذا تم تغيير جرعة أي من أدويتك الحالية أو إذا كنت تستهلك<br />بانتظام الكحول يجب عليك إخبار الطبيب بذلك.<br />إذا كان من المقرر أن تخضع للتخدير، فعليك أن تخبر الطبيب<br />.&trade; أو طبيب الأسنان أنك تستخدم بريموكوم<br />الحمل و الإرضاع<br />إستشيري طبيبك أو الصيدلي قبل إستعمال أي دواء و أخبري<br />طبيبك إذا كنتِ حاملاً أو تخططين للحمل.<br />قطرة للعين خلال فترة الحمل &trade; لا ينبغي إستخدام بريموكوم<br />ما لم يوصي الطبيب بضرورة ذلك.<br />قطرة للعين أثناء فترة الرضاعة &trade; لا ينبغي إستخدام بريموكوم<br />الطبيعية لأن التيمولول يمكن أن يمر من خلال لبن الأم.<br />إستشيري طبيبك قبل إستعمال أي دواء أثناء الرضاعة الطبيعية.<br />القيادة و تشغيل الآلات<br />النعاس والتعب أو عدم وضوح الرؤية &trade; قد يسبب بريموكوم<br />في بعض المرضى. لا تقم بالقيادة أو إستخدام أي أدوات أو<br />آلات حتى تزول تلك الأعراض. إذا واجهت أي مشاكل،<br />إستشير طبيبك.<br />قطرة للعين: &trade; معلومات هامة عن بعض مكونات بريموكوم<br />العدسات اللاصقة<br />بينما العدسات اللاصقة الخاصة بك &trade; &bull; لا تستخدم بريموكوم<br />في عينيك. انتظر ۱٥ دقيقة على الأقل بعد استخدام<br />قبل وضع العدسات الخاصة بك مرة أخرى. &trade; بريموكوم<br />كلوريد ) &trade; &bull; قد تسبب المادة الحافظة في بريموكوم<br />البنزالكونيوم) تهيج العين وكما هو معروف بأنها تسبب تغيير<br />لون العدسات اللاصقة اللينة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&trade; إستخدم دائما بريموكوم قطرة للعين تماماً كما وصفها لك<br />الطبيب. إذا كنت غير متأكداً استشر طبيبك أو الصيدلي.<br />في الرضع أقل من عمر &trade; لا ينبغي أن يٌستخدم بريموكوم<br />سنتين، و عادة لا ينبغي أن يستخدم في الأطفال و المراهقين<br />۱۷ سنة). - الذين تتراوح أعمارهم بين ( ۲<br />&trade; الجرعة المعتادة هي نقطة واحدة من بريموكوم في العين<br />مرتين في اليوم بفارق حوالى ۱۲ ساعة. لا تغير الجرعة أو<br />تتوقف عن الإستخدام بدون استشارة طبيبك.<br />&trade; إذا كنت تستخدم بريموكوم قطرة للعين مع أي قطرات<br />أخرى للعين قم بالإنتظار ٥ دقائق على الأقل بين إستخدام<br />&trade; بريموكوم قطرة للعين والقطرة الأخرى.<br />إرشادات إستخدام قطرات العين<br />إغسل اليدين قبل فتح زجاجة. قم بإمالة رأسك الى الخلف<br />وأنظر إلي السقف.<br />۱. إسحب الجفن السفلي إلى أسفل برفق حتى يتكون جيب<br />صغير.<br />۲. حرك الزجاجة رأسا على عقب، اضغط عليها لإخراج قطرة<br />واحدة في كل عين تحتاج لعلاج.<br />۳. اترك الجفن السفلي، و اغمض عينك.<br />٤. استمر في إغماض العين واضغط بإصبعك على ركن العين<br />(مكان التقاء العين بالأنف) لمدة دقيقتين. وهذا يساعد على وقف<br />في باقي الجسم. &trade; دخول بريموكوم<br />إذا لم تدخل النقطة في عينيك، حاول مرة أخرى.<br />لتجنب التلوث، لا تدع طرف القطارة يلمس عينيك أو أي شيء<br />آخر. وضع الغطاء الخلفي على القطارة لغلقها مباشرة بعد<br />استخدامها.<br />&trade; إذا استخدمت بريموكوم قطرة للعين بكمية أكثر من<br />المطلوب:<br />البالغين<br />&trade; إذا كنت تستخدم بريموكوم أكثر مما يجب، فمن غير<br />المحتمل أن تسبب لك أي ضرر. استعمل الجرعة التالية في<br />موعدها كالمعتاد. إذا كنت قلقا، تحدث مع طبيبك أو الصيدلي.<br />الرضع والأطفال<br />قد تم الإبلاغ عن العديد من حالات الجرعة الزائدة في الرضع<br />والأطفال الذين يتلقون بريمونيدين ( واحد من مكونات<br />كجزء من العلاج الطبي للجلوكوما. وتشمل<br />العلامات النعاس، التثاقل، انخفاض درجة حرارة الجسم ،<br />الشحوب و صعوبة التنفس. إذا حدث ذلك، اتصل بطبيبك فوراً.<br />البالغين والأطفال<br />&nbsp; إذا تم ابتلاع بريموكوم<br />بطبيبك فوراً. بطريق الخطأ يجب عليك الاتصال<br />&nbsp;إذا نسيت إستخدام بريموكوم قطرة للعين<br />إذا نسيت إستخدام بريموكوم قم بوضع نقطة واحدة فى كل ،<br />عين تحتاج العلاج في أسرع وقت ممكن ومن ثم إرجع إلى<br />نظام جرعاتك المعتاد. لا تستعمل جرعة مضاعفة لتعويض<br />الجرعة المنسية.<br />إذا توقفت عن إستخدام بريموكوم قطرة للعين<br />ينبغي أن يستخدم بريموكوم<br />صحيح. يومياً لكى يزاول مفعوله بشكل<br />إذا كان لديك أي أسئلة أخرى عن إستخدام هذا المستحضر،<br />فإسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية الأخرى، يمكن أن يؤدى بريموكوم<br />للعين في حدوث آثار جانبية بالرغم من عدم تعرض جميع<br />الأشخاص لها. إذا واجهت أي من الآثار الجانبية التالية، يرجى<br />الاتصال بطبيبك على الفور:<br />&bull; قصور القلب (على سبيل المثال ألم في الصدر) أو عدم<br />انتظام نظم القلب<br />&bull; زيادة أو نقصان معدل ضربات القلب أو انخفاض ضغط الدم<br />المجموعات التالية تصف فرصة حدوث الأعراض الجانبية:<br />غير معروفة: لا يمكن تقدير تكرارها من البيانات المتاحة<br />شائعة جداً: تحدث مع أكثر من ۱ فى كل ۱۰ مرضى<br />شائعة: تحدث مع أقل من ۱ فى كل ۱۰ مرضى<br />غير شائعة: تحدث مع أقل من ۱ فى كل ۱۰۰ مريض<br />&trade; قد تحدث الآثار الجانبية التالية عند استعمال بريموكوم<br />تؤثر على العين<br />شائعة جداً: احمرار العين أو إحساس حارق.<br />شائعة:<br />&bull; وخز أو ألم في العين<br />&bull; رد فعل تحسسي في العين أو على الجلد حول العين<br />&bull; تشققات صغيرة علي سطح العين (مع أو بدون التهاب)<br />&bull; تورم، احمرار أو التهاب في الجفن<br />&bull; تهيج، أو الإحساس بوجود شيء داخل العين<br />&bull; حكة العين والجفن<br />&bull; جُرَيبات أو بقع بيضاء على الطبقة الشفافة التي تغطي سطح<br />العين<br />&bull; اضطراب الرؤية<br />&bull; تدميع<br />&bull; جفاف العين<br />&bull; لزوجة في العين<br />غير شائعة<br />&bull; صعوبة في رؤية واضحة<br />&bull; تورم أو التهاب في الطبقة الشفافة التي تغطي سطح العين<br />&bull; عيون متعبة<br />&bull; حساسية للضوء<br />&bull; ألم الجفن<br />&bull; تحول الطبقة الشفافة التي تغطي سطح العين إلى اللون<br />الأبيض.<br />&bull; تورم أو التهاب مناطق تحت سطح العين<br />&bull; عوائم أمام العيون<br />غير معروفة<br />&bull; عدم وضوح الرؤية<br />الأعراض المؤثرة على الجسم:<br />شائعة:<br />&bull; ارتفاع ضغط الدم<br />&bull; اكتئاب<br />&bull; نعاس<br />&bull; صداع<br />&bull; جفاف الفم<br />&bull; ضعف عام<br />غير شائعة:<br />&bull; قصور القلب<br />&bull; عدم انتظام دقات القلب<br />&bull; دوار خفيف<br />&bull; إغماء<br />&bull; أنف جاف<br />&bull; مذاق غير طبيعي<br />&bull; غثيان<br />&bull; إسهال<br />غير معروفة:<br />&bull; زيادة أو نقص معدل ضربات القلب<br />&bull; انخفاض ضغط الدم<br />&bull; احمرار الوجه<br />بعض من هذه الآثار قد يكون راجعا إلى حساسية من أي من<br />المكونات. وقد شوهدت آثار جانبية إضافية مع بريمونيدين أو<br />.&trade; تيمولول، و بالتالي يحتمل أن تحدث مع بريموكوم<br />وقد شوهدت الآثار الجانبية الإضافية التالية مع بريمونيدين:<br />- التهاب في العين، صغر حجم حدقة العين، صعوبة في النوم،<br />أعراض مشابهة للزكام، ضيق التنفس، أعراض متعلقة بالمعدة<br />و الهضم، أمراض الحساسية العامة، ردود فعل الجلد تشمل<br />الاحمرار، تورم الوجه، حكة، طفح جلدي و إتساع في الأوعية<br />الدموية.<br />&trade; مثل أدوية العيون الأخرى، يتم امتصاص بريموكوم<br />(بريمونيدين / تيمولول) في الدم. قد يتسبب امتصاص<br />تيمولول، وهو من حاصرات بيتا و أحد مكونات<br />في آثار جانبية مماثلة لتلك التي تظهر مع إستخدام حاصرات<br />بيتا التي يتم حقنها عن طريق الوريد أو التي تؤخذ عن طريق<br />الفم. حدوث آثار جانبية بعد الاستخدام الموضعي بالعيون<br />أقل مما هو عليه عندما تؤخذ الأدوية على سبيل المثال عن<br />طريق الفم أو الحقن. وتشمل الآثار الجانبية المذكورة ردود<br />الفعل المشاهدة مع مجموعة حاصرات بيتا عندما تستخدم<br />لعلاج أمراض العيون:<br />- تفاعلات تحسسية عامة، تشمل تورم تحت الجلد (التي يمكن<br />أن تحدث في مناطق مثل الوجه والأطراف، ويمكن أن تعيق<br />مجرى الهواء مما قد يسبب صعوبة في البلع أو التنفس)،<br />الشرى (أو طفح جلدي وحكة)، طفح جلدي موضعى أو عام،<br />حكة، تفاعلات تحسسية مفاجئة وحادة تهدد الحياة<br />- انخفاض مستويات السكر في الدم<br />- صعوبة في النوم (الأرق)، كوابيس، فقدان الذاكرة<br />- سكتة دماغية، انخفاض تدفق الدم إلى الدماغ، زيادة علامات<br />وأعراض الوهن العضلي الوبيل (اضطراب العضلات)،<br />أحاسيس غير عادية (مثل وخز الإبر والدبابيس)<br />- التهاب في القرنية، إنفصال في الطبقة تحت شبكية العين<br />التي تحتوي على الأوعية الدموية بعد جراحة الترشيح والتي<br />قد تسبب اضطرابات بصرية، نقص حساسية القرنية، تآكل<br />القرنية ( تلف في الطبقة الأولى من مقلة العين)، تدلى الجفن<br />العلوي (يجعل العين نصف مغلقة)، رؤية مزدوجة<br />- ألم في الصدر، وذمة (تراكم السوائل)، تغييرات في إيقاع أو<br />سرعة ضربات القلب، وهو نوع من اضطراب نظم القلب،<br />نوبات قلبية ، فشل القلب<br />- ظاهرة رينود، برودة اليدين والقدمين<br />- إنقباض الشعب الهوائية في الرئة (غالبا في المرضى الذين<br />يعانون من مرض موجود من قبل) صعوبة في التنفس والسعال<br />- عسر الهضم وآلام البطن و القيء<br />- تساقط الشعر، طفح جلدي مع مظهر أبيض فضي اللون<br />(طفح جلدي شبيه بالصدفية) أو تفاقم مرض الصدفية، طفح<br />جلدي<br />- آلام العضلات ليست بسبب ممارسة التمارين.<br />- ضعف جنسي، وانخفاض الرغبة الجنسية<br />- ضعف العضلات / التعب<br />إذا تحول أي من الآثار الجانبية إلى مرحلة أكثر خطورة أو إذا<br />لاحظت حدوث آثار جانبية أخرى غير مدرجة في هذه النشرة<br />يرجى إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; إحفظ الزجاجة في العلبة الخارجية لحمايتها من الضوء.<br />&bull; يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تستخدم بريموكوم قطرة للعين بعد انتهاء تاريخ &bull;<br />الصلاحية و المدون على الملصقة الموجودة على الزجاجة<br />. وعلى العبوة الكرتونية بعد كلمة EXP<br />قطرة للعين تكون معقمة عند فتحها لأول مرة،<br />من المهم أن تظل القطرات نظيفة بأكبر قدر ممكن خلال<br />الإستخدام.<br />&bull; يتلف الدواء بعد ۳۰ يوماً من فتح الغطاء.<br />&bull; لا يتم التخلص من الأدوية عن طريق مياه الصرف أو<br />النفايات المنزلية. إسأل الصيدلي عن طريقة التخلص من<br />الأدوية الغير مرغوب فيها فسوف تساعد هذه الإجراءات على<br />حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المواد الفعالة هي بريمونيدين تارتارات و التيمولول.<br />&bull; يحتوي كل مل على ۲ ملجم بريمونيدين تارتارات و<br />ماليات التيمولول تعادل ٥ ملغ من التيمولول.<br />&bull; المكونات الأخرى هي: كلوريد البنزالكونيوم (كمادة حافظة)،<br />صوديوم ثنائي هيدروجين الفوسفات اللامائي ، ثنائي صوديوم<br />فوسفات الهيدروجين اللامائي ، هيدروكسيد الصوديوم (لضبط<br />درجة الحموضة) و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>بريموكوم قطرة للعين، هو محلول رائق، لونه أصفر<br />مخضر وخالي من الجسيمات.<br />بريموكوم قطرة للعين، محلول ٥ مل في قطارة معتمة من&nbsp;<br />البولي إيثيلين منخفض الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة،<br />المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الإلكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12-09-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Brimocom™ 2 mg/ml / 5 mg/ml eye drops, solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 ml solution contains:
2.0 mg Brimonidine Tartrate
5.0 mg Timolol equivalent to 6.84 mg Timolol Maleate Contains Benzalkonium chloride 0.05 mg/mL
For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.
Clear, greenish yellow colored solution free from visible particles, filled in 10 mL LOPE opaque bottles.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:38.15pt">Reduction of intraocular pressure (TOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:35.45pt">To avoid contamination of the eye or eye drops do not allow the dropper tip to come into contact with any surface.</p><p style="margin-left:33.0pt"><em><u>Recommended dosage in adults (including the elderly)</u></em></p><p style="margin-left:33.0pt; margin-right:52.0pt; text-align:justify">The recommended dose is one drop of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution in the affected eye(s) twice daily, approximately 12 hours apart. Tf more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.</p><p style="margin-right:33.15pt">As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctual occlusion) or eyelids are closed for two minutes. This should be performed immediately following the instillation of each drop. This may result in a decrease of systemic side effects and an increase in local activity.</p><p style="margin-left:32.25pt; margin-right:0in"><em><u>Use in renal and hepatic impairment</u></em></p><p style="margin-left:32.25pt; margin-right:35.15pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has not been studied in patients with hepatic or renal impairment. Therefore, caution should be used in treating such patients.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:33.0pt; margin-right:0in"><em><u>Use in children and adolescents</u></em></p><p style="margin-left:33.0pt; margin-right:34.75pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution is contraindicated in neonates and infants (less than 2 years of age) (see section 4.3 Contraindications, section 4.4 Special warnings and precautions for use, section 4.8 Undesirable effects and section 4.9 Overdose).</p><p style="margin-right:35.1pt">The safety and effectiveness of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution in children and adolescents (2 to 17 years of age) have not been established and therefore, its use is not recommended in children or adolescents (see also section 4.4 and section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients.
•	Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
•	Sinus bradycardia, sick sinus syndrome sino-atrial block, second or third degree atrioventricular block not controlled with a pace-maker, overt cardiac failure, cardiogenic shock.
•	Use in neonates and infants (less than 2 years of age) (see section 4.8)
•	Patients receiving monoamine oxidase (MAO) inhibitor therapy.
•	Patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:36.1pt">Children of 2 years of age and above, especially those in the 2-7 age range and/or weighing :S20 Kg should be treated with caution and closely monitored due to the high incidence and severity of somnolence. The safety and effectiveness of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution in children and adolescents (2 to 17 years of age) have not been established (see section 4.2 and section 4.8).</p><p style="margin-right:33.15pt">Some patients have experienced ocular allergic type reactions (allergic conjunctivitis and allergic blepharitis) with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution in clinical trials. Allergic conjunctivitis was seen in 5.2% of patients. Onset was typically between</p><p style="margin-left:33.0pt; margin-right:58.1pt; text-align:justify">3 and 9 months resulting in an overall discontinuation rate of 3.1%. Allergic blepharitis was uncommonly reported (&lt;1%). If allergic reactions are observed, treatment with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution should be discontinued.</p><p style="margin-left:33.0pt; margin-right:81.1pt; text-align:justify">Delayed ocular hypersensitivity reactions have been reported with brimonidine tartrate ophthalmic solution 0.2%, with some reported to be associated with an increase in IOP.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.7pt; margin-right:40.05pt">Like other topically applied ophthalmic agents, Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution may be absorbed systemically. No enhancement of the systemic absorption of the individual active substances has been observed. Due to beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p style="margin-left:33.0pt; margin-right:0in"><em><u>Cardiac disorders:</u></em></p><p style="margin-left:33.0pt; margin-right:37.45pt">In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.</p><p style="margin-right:39.45pt">Due to its negative effect on conduction time, beta-blocker should only be given with caution to patients with first degree heart block.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:69.1pt">As with systemic beta-blockers, if discontinuation of treatment is needed in patients with coronary heart disease, therapy should be withdrawn gradually to avoid rhythm disorders, myocardial infarct or sudden death.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Vascular disorders:</u></em></p><p style="margin-left:33.0pt; margin-right:35.45pt">Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&#39;s disease or Raynaud&#39;s syndrome) should be treated with caution.</p><p>&nbsp;</p><p style="margin-left:33.0pt; text-align:justify"><em><u>Respiratory disorders:</u></em></p><p style="margin-left:33.0pt; margin-right:48.1pt; text-align:justify">Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.</p><p style="margin-right:36.8pt; text-align:justify">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.</p><p style="margin-left:32.25pt; margin-right:0in"><em><u>Hypoglycaemia/diabetes</u></em></p><p style="margin-left:32.25pt; margin-right:64.2pt">Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.</p><p style="margin-left:33.0pt; margin-right:0in"><em><u>Hyperthyroidism</u></em></p><p>Beta-blockers may also mask the signs of hyperthyroidism.</p><p style="margin-left:33.0pt; margin-right:45.05pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution must be used with caution in patients with metabolic acidosis and untreated phaeochromocytoma.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Corneal diseases</u></em></p><p style="margin-left:33.0pt; margin-right:41.75pt">Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Other beta-blocking agents</u></em></p><p style="margin-left:33.0pt; margin-right:50.45pt">The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed. The use of two topical beta- adrenergic blocking agents is not recommended (see section 4.5).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Anaphylactic reactions</u></em></p><p style="margin-left:33.0pt; margin-right:37.85pt">While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergans and unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Choroidal detachment</u></em></p><p style="margin-left:33.0pt; margin-right:56.1pt">Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. Timolol, acetazolamide) after filtration procedures.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em><u>Surgical anaesthesia</u></em></p><p style="margin-left:33.0pt; margin-right:54.45pt">Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of adrenaline. The anaesthetist must be informed if the patient is receiving Timolol.</p><p style="margin-right:37.45pt">In patients with severe renal impairment on dialysis, treatment with Timolol has been associated with pronounced hypotension.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:35.45pt">The preservative in Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution, Benzalkonium chloride, may cause eye irritation. Remove contact lenses prior to application and</p><p style="margin-left:32.05pt; margin-right:53.7pt">wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses. Avoid contact with soft contact lenses.</p><p style="margin-left:32.05pt; margin-right:35.35pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has not been studied in patients with closed-angle glaucoma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:35.45pt">No interaction studies have been performed with the Brimonidine, Timolol fixed combination. Although specific drug interactions studies have not been conducted with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution, the theoretical possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:33.6pt">There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, , beta-adrenergic blocking agents, anti-arrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics or guanethidine.Also, after the application of brimonidine, very rare (&lt;1 in 10,000) cases of hypotension have been reported. Caution is therefore advised when using Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution with systemic antihypertensives.</p><p style="margin-right:39.1pt">Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally. Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents. Beta-blockers can mask the signs and symptoms of hypoglycaemia (see 4.4 Special warnings and precautions for use).</p><p style="margin-right:56.95pt">The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-blockers.</p><p style="margin-right:41.4pt">Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and Timolol.</p><p style="margin-right:41.15pt">Concomitant use of a beta-blocker with anaesthetic drugs may attenuate compensatory tachycardia and increase the risk of hypotension (see section 4.4), and therefore the anaesthetist must be informed if the patient is using Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution.</p><p style="margin-right:38.4pt">Caution must be exercised if Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution is used concomitantly with iodine contrast products or intravenously administered lidocain.</p><p style="margin-left:33.0pt; margin-right:61.1pt">Cimetidine, hydralazine and alcohol may increase the plasma concentrations of Timolol. No data on the level of circulating catecholamines after Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution administration are available. Caution, however, is</p><p style="margin-left:33.0pt; margin-right:39.8pt">advised in patients taking medication which can affect the metabolism and uptake of circulating amines e.g. chlorpromazine, methylphenidate, reserpine.</p><p style="margin-left:33.0pt; margin-right:35.45pt">Caution is advised when initiating (or changing the dose of) a concomitant systemic agent (irrespective of pharmaceutical form) which may interact with a-adrenergic agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor e.g. (isoprenaline, prazosin).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt; margin-right:35.45pt">Although specific drug interactions studies have not been conducted with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution, the theoretical possibility of an additive TOP lowering effect with prostamides, prostaglandins, carbonic anhydrase inhibitors and pilocarpine should be considered.</p><p style="margin-right:33.45pt">Brimonidine is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and patients on antidepressants which affect noradrenagic transmission (e.g. tricyclic antidepressants and miaserin), (see section 4.3).Patients who have been receiving MAOT therapy should wait 14 days after discontinuation before commencing treatment with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:0in"><em>Pregnancy</em></p><p style="margin-left:33.0pt; margin-right:34.15pt">There are no adequate data for the use of the Brimonidine Timolol fixed combination in pregnant women. Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section 4.2.</p><p style="margin-left:33.0pt"><em>Brimonidine tartrate</em></p><p style="margin-left:33.0pt; margin-right:35.75pt">There are no adequate data from the use of Brimonidine Tartrate in pregnant women. Studies in animals have shown reproductive toxicity at high maternotoxic doses (see section 5.3 Preclinical safety data). The potential risk for humans is unknown.</p><p style="margin-left:33.0pt"><em>Timolol</em></p><p style="margin-left:33.0pt; margin-right:39.75pt">Studies in animals have shown reproductive toxicity at doses significantly higher than would be used in clinical practice (see 5.3).</p><p style="margin-right:44.45pt">Epidemiological studies have not revealed malformative effects but have shown a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. Tn addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and</p><p style="margin-left:33.9pt; margin-right:39.85pt; text-align:justify">hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution is administered in pregnancy up to the time of delivery, the neonate should be carefully monitored during the first days of life.</p><p style="margin-left:33.9pt; margin-right:396.05pt"><em>Lactati Brimonidine Tartrate</em></p><p style="margin-left:33.9pt; margin-right:56.8pt">It is not known if Brimonidine is excreted in human milk but it is excreted in the milk of the lactating rat.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:33.0pt; margin-right:0in"><em>Timolol</em></p><p style="margin-left:33.0pt; margin-right:36.15pt">Beta-blockers are excreted in breast milk. However, at therapeutic doses of Timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2 Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution should not be used by women breast-feeding infants.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:36.75pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has minor influence on the ability to drive and use machines. Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution may cause transient blurring of vision, visual disturbance, fatigue and/or drowsiness which may impair the ability to drive or operate machines. The patient should wait until these symptoms have cleared before driving or using machinery.</p><p style="margin-left:33.0pt; margin-right:46.4pt">&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:46.4pt">Based on 12 month clinical data, the most commonly reported ADRs were conjunctival hyperaemia (approximately 15% of patients) and burning sensation in the eye (approximately 11% of patients). The majority of these cases was mild and led to discontinuation rates of only 3.4% and 0.5% respectively.</p><p style="margin-right:63.75pt">The following adverse drug reactions were reported during clinical trials with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution:</p><p style="margin-left:33.0pt; margin-right:0in"><em>Eye disorders</em></p><p>Very common (&gt;1/10): conjunctival hyperaemia, burning sensation</p><p style="margin-left:33.0pt; margin-right:38.15pt">Common (&gt;1/100, &lt;1/10): stinging sensation in the eye, allergic conjunctivitis, corneal erosion, superficial punctuate keratitis, eye pruritus, conjunctival folliculosis, visual disturbance, blepharitis, epiphora, eye dryness, eye discharge, eye pain, eye irritation, foreign body sensation</p><p style="margin-left:33.0pt; margin-right:46.15pt">Uncommon (&gt;1/1000, &lt;1/100): visual acuity worsened, conjunctival oedema, follicular conjunctivitis, allergic blepharitis, conjunctivitis, vitreous floater, asthenopia, photophobia, papillary hypertrophy, eyelid pain, conjunctival blanching, corneal oedema, corneal infiltrates, vitreous detachment</p><p style="margin-left:33.0pt"><em>Psychiatric disorders</em></p><p>Common (&gt;1/100, &lt;1/10): depression</p><p style="margin-left:33.0pt; margin-right:0in"><em>Nervous system disorders</em></p><p style="margin-left:33.0pt; margin-right:256.5pt">Common (&gt;1/100, &lt;1/10): somnolence, headache Uncommon (&gt;1/1000, &lt;1/100): dizziness, syncope <em>Cardiac disorders</em></p><p>Uncommon (&gt;1/1000, &lt;1/100): congestive heart failure, palpitations</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em>Vascular disorders</em></p><p>Common (&gt;1/100, &lt;1/10): hypertension</p><p style="margin-left:33.0pt; margin-right:241.45pt"><em>Respiratory, thoracic and mediastinal disorders </em>Uncommon (&gt;1/1000, &lt;1/100): rhinitis, nasal dryness <em>Gastrointestinal disorders</em></p><p>Common (&gt;1/100, &lt;1/10): oral dryness</p><p>Uncommon (&gt;1/1000, &lt;1/100): taste perversion, nausea, diarrhoea.</p><p style="margin-left:33.0pt; margin-right:0in"><em>Skin and subcutaneous tissue disorders</em></p><p style="margin-left:33.0pt; margin-right:141.55pt">Common (&gt;1/100, &lt;1/10): eyelid oedema, eyelid pruritus, eyelid erythema Uncommon (&gt;1/1000, &lt;1/100): allergic contact dermatitis</p><p style="margin-left:33.0pt; margin-right:0in"><em>General disorders and administration site conditions</em></p><p>Common (&gt;1/100, &lt;1/10): asthenic conditions</p><p style="margin-left:33.0pt; margin-right:45.15pt">The following adverse drug reactions have been reported since Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has been marketed:</p><p style="margin-left:33.0pt; margin-right:0in"><em>Eye disorders:</em>Not known: Vision blurred</p><p style="margin-left:33.0pt; margin-right:0in"><em>Cardiac disorders</em></p><p>Not known: arrhythmia, bradycardia, tachycardia</p><p style="margin-left:33.0pt; margin-right:0in"><em>Vascular disorders</em></p><p>Not known: hypotension</p><p style="margin-left:33.0pt; margin-right:0in"><em>Skin disorders:</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p>Not known: Erythema facial</p><p style="margin-left:33.0pt; margin-right:44.1pt">Additional adverse events that have been seen with one of the components and may potentially occur also with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution:</p><p style="margin-left:33.0pt; margin-right:0in"><em>Brimonidine</em></p><p style="margin-left:33.0pt; margin-right:0in"><em>Eye disorders: </em>iritis, iridocyclitis (anterior uveitis), miosis</p><p style="margin-left:33.0pt; margin-right:0in"><em>Psychiatric disorders: </em>insomnia</p><p style="margin-left:33.0pt; margin-right:0in"><em>Respiratory, thoracic and mediastinal disorders: </em>upper respiratory symptoms, dyspnoea</p><p style="margin-left:33.0pt; margin-right:0in"><em>Gastrointestinal disorders: </em>gastrointestinal symptoms</p><p style="margin-left:33.0pt; margin-right:0in"><em>General disorders and administration site conditions: </em>systemic allergic reactions</p><p style="margin-left:33.0pt; margin-right:.95in"><em>Skin and subcutaneous tissue disorders: </em>- Skin reaction including erythema, face oedema, pruritus, rash and vasodilatation</p><p style="margin-right:55.4pt">In cases where Brimonidine has been used as part of the medical treatment of congenital glaucoma, symptoms of Brimonidine overdose such as loss of consciousness, lethargy, somnolence, hypotension, hypotonia, bradycardia, hypothermia, cyanosis, pallor, respiratory depression and apnoea have been reported in neonates and infants (less than 2 years of age) receiving Brimonidine (see section 4.3).</p><p style="margin-left:33.0pt; margin-right:37.8pt">A high incidence and severity of somnolence has been reported in children of 2 years of age and above, especially those in the 2-7 age range and/or weighing :S20 Kg (see section 4.4).</p><p style="margin-left:33.0pt"><em>Timolol</em></p><p style="margin-left:33.0pt; margin-right:34.55pt">Like other topically applied ophthalmic drugs, Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution (Brimonidine Tartrate/ Timolol) is absorbed into the systemic circulation. Absorption of Timolol may cause similar undesirable effects as seen with systemic beta-blocking agents.</p><p style="margin-right:45.45pt">Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p style="margin-left:33.0pt; margin-right:48.05pt">Additional adverse reactions that have been seen with ophthalmic beta-blockers and may potentially occur also with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution are listed below:</p><p style="margin-right:37.8pt"><em>Immune system disorders: </em>Systemic allergic reactions including angioedema, urticaria, localised and generalised rash, pruritis, anaphylactic reaction</p><p style="margin-left:33.0pt"><em>Metabolism: </em>Hypogycaemia</p><p style="margin-left:33.0pt; margin-right:0in"><em>Psychiatric disorders: </em>Insomnia, nightmares, memory loss</p><p><em>Nervous system disorders: </em>Cerebrovascular accident, cerebral ischemia, increases in signed and symptoms of myasthenia gravis, paraesthesia</p><p style="margin-right:33.1pt"><em>Eye disorders: </em>keratitis, choroidal detachment following filtration sugery (see section 4.4 Special warnings and special precautions for use), decreased corneal sensitivity, corneal erosion, ptosis, diplopia</p><p style="margin-left:33.0pt"><em>Cardiac disorders: </em>chest pain, oedema, atrioventricular block, cardiac arrest, cardiac failure</p><p style="margin-left:33.0pt; margin-right:0in"><em>Vascular disorders: </em>Raynaud&#39;s phenomenon, cold hands and feet.</p><p style="margin-left:33.0pt; margin-right:34.65pt"><em>Respiratory, thoracic, and mediastinal disorders: </em>Bronchospasm (predominantly in patients with pre-existing bronchospatic disease), dyspnoea, cough.</p><p style="margin-left:33.0pt; margin-right:0in"><em>Gastrointestinal disorders: </em>dyspepsia, abdominal pain, vomiting</p><p style="margin-left:33.0pt; margin-right:33.05pt"><em>Skin and subcutaneous tissue disorders: </em>Alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash.</p><p style="margin-left:33.0pt"><em>Musculoskeletal and connective tissue disorders: </em>Myalgia</p><p style="margin-left:33.0pt; margin-right:0in"><em>Reproductive system and breast disorders: </em>Sexual dysfunction, decreased libido</p><p style="margin-left:33.0pt; margin-right:0in"><em>General disorders and administration site conditions: </em>Fatigue.</p><p style="margin-left:33.0pt; margin-right:0in"><strong><u>Reporting of suspected adverse reactions</u></strong></p><p style="margin-left:33.0pt; margin-right:40.8pt">Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of benefit/risk balance of the medicinal product.</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-2057662<br />o Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:65.75pt">Rare reports of overdosage with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution in humans resulted in no adverse outcome. Treatment of an overdose includes supportive and symptomatic therapy; a patient&#39;s airway should be maintained.</p><p style="margin-left:33.0pt"><em><u>Brimonidine</u></em></p><p style="margin-left:33.0pt; margin-right:0in"><em><u>Ophthalmic overdose (Adults):</u></em></p><p style="margin-left:33.0pt; margin-right:45.2pt">In those cases received, the events reported have generally been those already listed as adverse reactions.</p><p style="margin-left:33.0pt"><em><u>Systemic overdose resulting from accidental ingestion (Adults):</u></em></p><p style="margin-left:33.0pt; margin-right:46.75pt">There is very limited information regarding accidental ingestion of Brimonidine in adults. The only adverse event reported to date was hypotension. It was reported that the hypotensive episode was followed by rebound hypertension. Oral overdoses of other alpha-2-agonists have</p><p style="margin-left:33.0pt; margin-right:50.3pt; text-align:justify">been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression and seizure.</p><p style="margin-left:33.0pt; margin-right:0in; text-align:justify"><em><u>Paediatric population</u></em></p><p style="margin-left:33.0pt; margin-right:37.1pt">Reports of serious adverse effects following inadvertent ingestion of Alphagan by paediatric subjects have been published or reported to Allergan. The subjects experienced symptoms of CNS depression, typically temporary coma or low level of consciousness, lethargy, somnolence, hypotonia, bradycardia, hypothermia, pallor, respiratory depression and apnoea, and required admission to intensive care with intubation if indicated.All subjects were reported to have made a full recovery, usually within 6-24 hours.</p><p style="margin-left:33.0pt; margin-right:0in"><em><u>Timolol</u></em></p><p style="margin-left:33.0pt; margin-right:35.45pt">Symptoms of systemic Timolol overdose include: bradycardia, hypotension, bronchospasm, headache, dizziness and cardiac arrest. A study of patients showed that Timolol did not dialyse readily.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:0in"><em>Pharmacotherapeutic group: </em>Ophthalmological - antiglaucoma preparations and miotics - beta- blocking agents - Timolol, combinations</p><p style="margin-left:33.0pt; margin-right:0in"><em>ATC code: </em>S0lED5l</p><p style="margin-left:33.0pt; margin-right:0in"><em>Mechanism of action</em></p><p style="margin-left:33.0pt; margin-right:39.8pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution consists of two active substances: Brimonidine Tartrate and Timolol Maleate. These two components decrease elevated intraocular pressure (TOP) by complementary mechanisms of action and the combined effect results in additional TOP reduction compared to either compound administered alone.</p><p style="margin-right:38.75pt">Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has a rapid onset of action.</p><p style="margin-left:33.0pt; margin-right:38.15pt">Brimonidine Tartrate is an alpha-2 adrenergic receptor agonist that is l000-fold more selective for the alpha-2 adrenoceptor than the alpha-l adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:35.45pt">Tt is thought that Brimonidine Tartrate lowers TOP by enhancing uveoscleral outflow and reducing aqueous humour formation.</p><p>Timolol is a beta<sub>l</sub> and beta<sub>2</sub> non-selective adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic</p><p style="margin-left:31.15pt; margin-right:0in">(membrane-stabilising) activity. Timolol lowers TOP by reducing aqueous humour formation.</p><p style="margin-left:31.15pt; margin-right:40.3pt">The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta-adrenergic stimulation is probable.</p><p style="margin-left:32.05pt; margin-right:0in"><em>Clinical effects</em></p><p style="margin-left:31.15pt; margin-right:37.3pt">Tn three controlled, double-masked clinical studies, Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution (twice daily) produced a clinically meaningful additive decrease</p><p style="margin-left:33.0pt; margin-right:36.6pt; text-indent:-1.85pt">in mean diurnal TOP compared with Timolol (twice daily) and Brimonidine (twice daily or three times a day) when administered as monotherapy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt; margin-right:32.1pt">Tn a study in patients whose TOP was insufficiently controlled following a minimal 3-week run-in on any monotherapy, additional decreases in mean diurnal TOP of 4.5, 3.3 and 3.5 mmHg were observed during 3 months of treatment for Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution (twice daily), Timolol (twice daily) and Brimonidine (twice daily), respectively. Tn this study, at trough, a significant additional decrease in TOP could only be demonstrated on comparison with Brimonidine but not with Timolol, however a positive trend was seen with superiority at all other timepoints. Tn the pooled data of the other two trials statistical superiority versus Timolol was seen throughout.</p><p>Tn addition, the TOP-lowering effect of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution was consistently non-inferior to that achieved by adjunctive therapy of Brimonidine and Timolol (all twice daily).</p><p style="margin-right:41.45pt">The TOP-lowering effect of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution has been shown to be maintained in double-masked studies of up to 12 months.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt"><em>Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution</em></p><p style="margin-left:33.0pt; margin-right:33.45pt">Plasma Brimonidine and Timolol concentrations were determined in a crossover study comparing the monotherapy treatments to Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution treatment in healthy subjects. There were no statistically significant differences in Brimonidine or Timolol AUC between Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution and the respective monotherapy treatments. Mean plasma C<sub>max</sub> values for Brimonidine and Timolol following dosing with Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution were 0.0327 and 0.406 ng/ml respectively. <em>Brimonidine</em></p><p style="margin-right:35.45pt">After ocular administration of 0.2% eye drops solution in humans, plasma Brimonidine concentrations are low. Brimonidine is not extensively metabolised in the human eye and human</p><p style="margin-left:33.0pt; margin-right:66.45pt">plasma protein binding is approximately 29%. The mean apparent half-life in the systemic circulation was approximately 3 hours after topical dosing in man.</p><p style="margin-right:35.45pt">Following oral administration to man, Brimonidine is well absorbed and rapidly eliminated. The major part of the dose (around 74% of the dose) was excreted as metabolites in urine within five days; no unchanged drug was detected in urine. In vitro studies, using animal and human liver, indicate that the metabolism is mediated largely by aldehyde oxidase and cytochrome P450.</p><p>Hence, the systemic elimination seems to be primarily hepatic metabolism.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt; margin-right:38.75pt">Brimonidine binds extensively and reversibly to melanin in ocular tissues without any untoward effects. Accumulation does not occur in the absence of melanin.</p><p>Brimonidine is not metabolised to a great extent in human eyes.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:33.0pt"><em>Timolol</em></p><p style="margin-left:33.0pt; margin-right:34.1pt">After ocular administration of a 0.5% eye drops solution in humans undergoing cataract surgery, peak Timolol concentration was 898 ng/ml in the aqueous humour at one hour post-dose. Part of the dose is absorbed systemically where it is extensively metabolised in the liver. The half-life of Timolol in plasma is about 7 hours. Timolol is partially metabolised by the liver with Timolol and its metabolites excreted by the kidney. Timolol is not extensively bound to plasma protein.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:33.0pt; margin-right:36.8pt">The ocular and systemic safety profile of the individual components is well established. Non- clinical data reveal no special hazard for humans based on conventional studies of the individual components in safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenicity studies. Additional ocular repeated dose toxicity studies on Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution also showed no special hazard for humans.</p><p style="margin-left:33.0pt"><em>Brimonidine</em></p><p style="margin-left:33.0pt; margin-right:38.4pt">Brimonidine Tartrate did not cause any teratogenic effects in animals, but caused abortion in rabbits and postnatal growth reduction in rats at systemic exposures approximately 37-times and 134-times those obtained during therapy in humans, respectively.</p><p style="margin-left:33.0pt"><em>Timolol</em></p><p style="margin-left:0in"><em>&nbsp;</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p style="margin-right:47.45pt">In animal studies, beta-blockers have been shown to produce reduced umbilical blood flow, reduced foetal growth, delayed ossification and increased foetal and postnatal death, but no teratogenicity. With Timolol, embryotoxicity (resorption) in rabbit and foetotoxicity (delayed ossification) in rats have been seen at high maternal doses. Teratogenicity studies in mice, rats</p><p>&nbsp;</p><p style="margin-left:33.0pt; margin-right:78.35pt; text-align:justify">and rabbits, at oral doses of Timolol up to 4200 times of that in the human daily dose of Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution, showed no evidence of foetal malformation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Benzalkonium chloride (BAK) (10 % solution used)</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sodium Dihydrogen Phosphate Anhydrous</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Disodium Hydrogen Phosphate Anhydrous</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Sodium Hydroxide 1N to adjust pH</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life after first opening: Discard after 30 days of opening.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&uuml;&nbsp; <!--[endif]-->Do not store above 30&deg;C</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&uuml;&nbsp; <!--[endif]-->Keep out of the reach and sight of children.</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&uuml;&nbsp; <!--[endif]-->Keep the bottle in the outer carton to protect it from light.</p><p style="margin-left:69.0pt; margin-right:0in"><!--[if !supportLists]-->&uuml;&nbsp; <!--[endif]-->For external use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml of the Brimocom Ophthalmic Solution (Brimonidine Tartrate 0.2% w/v and Timolol 0.5% w/v Ophthalmic Solution) is filled in a pre-sterilized 10 ml white Low Density Polyethylene (LDPE) bottle with a pre-sterilized LDPE dropper and High Density Polyethylene (HDPE) pre- sterilized cap and packed with carton and PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Factory Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01-Sep-2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>